Ovarian tumours - immunohistochemistry

 

cytokeratins

CK7

CK20

CEA

EMA

Ca19.9

CA125

vimentin

S-100

SMA

desmin

inhibin

CD99

oestrogen and progesterone receptors

low MW

high MW

serous tumours

 17/172

10/172

+

-

 4/172

+

 

17/172

 

 4/172

 

 

-

 

 

endocervical-type mucinous tumours

 

 

+

-

(+)

+

 

 

 

 

 

 

-

 

+

intestinal type mucinous tumours

 

 

+

+

+

+

 

 

 

 

 

 

-

 

-

endometrioid tumours

 

 

 

 

 

+

 

 

 

 

 

 

-

 

 

Brenner tumours

 

 

+

-

+

+

+

 

 

 

 

 

-

 

 

granulosa cell tumours

30-60%

 

 

 

 

neg

 

 

100%4

50%4

90%4

-

+

90%

PR +ve3, ER -ve3

juvenile granulosa cell tumours

~50%

 

 

 

-

 

 

 

+

 

 

 

+

 

 

Sertoli(-Leydig) cell tumour

50%4

 

 

 

 

-

 

 

100%4

100%4 

 

 

+

 var

 

Leydig cell tumour

neg4

 

 

 

 

 

 

 

pos4

 

 

 

 

 

 

SCTAT

-

 

 

 

 

 

 

 

+

 

 

 

+

 

 

steroid cell tumours

30-50%

 

 

 

 

 

 

 

+

 

30%

 

+

 

 

small cell carcinoma

+

 

 

 

 

30-75%

 

 

+

 

 

 

-

 

 

See also: Melan-A (A103) immunostaining in ovarian sex cord stromal tumours.

One case of thyroglobulin-positivity in a series of 17 papillary serous carcinomas has been reported2.

Differential diagnoses

 

SCST

endometrioid carcinoma

broad spectrum anti-cytokeratins

positive, except pure Leydig cell tumours

positive

Cytokeratin 7

negative, except for Retiform areas of Sertoli-Leydig cell tumours5

positive, including 5/6 sex cord-like endometrioid carcinomas5

CD99

90% of granulosa cell tumours, variably in Sertoli-Leydig cell tumours6

positive in some sex cord-like endometrioid carcinoma (but not membranous staining)6

inhibin

positive ( vide supra)

negative

EMA

negative

usually positive, but may only be focal7

 

 

granulosa cell tumour

hypercalcaemic small cell carcinoma

yolk sac tumour

a-inhibin

positive

negative

negative; may be focally positive in hepatoid yolk sac tumour

CD99

positive

positive

negative

a-fetoprotein

negative

negative

positive

a-antitypsin

negative

negative

positive

CEA

negative

negative

positive

 

 

signet-ring stromal tumour

Krukenberg tumour

 

a-inhibin

positive

negative

EMA

negative

positive

SMA

positive

negative

CEA

negative

positive

pancytokeratin

negative

positive

 

References

Diagnostic histopathology of tumors. Edited by CDM Fletcher. 2nd edition. Churchill Livingstone. Pages 567-625.

2Keen, C. E., Szakacs, S., Okon, E., Rubin, J. S., Bryant, B. M. CA125 and thyroglobulin staining in papillary carcinomas of thyroid and ovarian origin is not completely specific for site of origin Histopathology 1999;34:113-117

3Kato, N., Fukase, M., Ono, I., Matsumoto, K., Okazaki, E., Motoyama, T. Sertoli-stromal cell tumor of the ovary: immunohistochemical, ultrastructural, and genetic studies. Hum Pathol 2001;32:796-802

4Zheng, W., Senturk, B.Z. and Parkash, V. Inhibin immunohistochemical staining: a practical approach for the surgical pathologist in the diagnoses of ovarian sex cord-stromal tumors. Adv Anat Pathol 2003;10:27-38.

5Guerrieri, C., Franlund, B., Malmstrom, H. and Boeryd, B. Ovarian endometrioid carcinomas simulating sex cord-stromal tumors: a study using inhibin and cytokeratin 7. Int J Gynecol Pathol 1998;17:266-71.

6Matias-Guiu, X., Pons, C. and Prat, J. Mullerian inhibiting substance, alpha-inhibin, and CD99 expression in sex cord-stromal tumors and endometrioid ovarian carcinomas resembling sex cord-stromal tumors. Hum Pathol 1998;29:840-5.

7Ordi, J., Schammel, D.P., Rasekh, L. and Tavassoli, F.A. Sertoliform endometrioid carcinomas of the ovary: a clinicopathologic and immunohistochemical study of 13 cases. Mod Pathol 1999;12:933-40.

8Rishi, M., Howard, L.N., Bratthauer, G.L. and Tavassoli, F.A. Use of monoclonal antibody against human inhibin as a marker for sex cord-stromal tumors of the ovary. Am J Surg Pathol 1997;21:583-9.

 

This page last revised 3.9.2001.